Cost-effectiveness analysis of dronedarone versus other anti-arrhythmic drugs for the treatment of atrial fibrillation--results for Canada, Italy, Sweden and Switzerland.

The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care
Jonas NilssonPeter Lindgren

Abstract

The ATHENA clinical trial enrolled 4,628 patients in 37 countries and evaluated the efficacy of dronedarone 400 mg twice daily versus placebo for the prevention of cardiovascular hospitalisation or death from any cause in patients with paroxysmal or persistent atrial fibrillation or atrial flutter. The trial showed a statistically significant 24% reduction in the primary endpoint cardiovascular hospitalisations or all-cause death. In the current paper, parameters that drive the cost-effectiveness of dronedarone on top of standard therapy versus likely comparators, i.e. amiodarone, sotalol and flecainide, were investigated by means of a health economic model based on the ATHENA clinical trial. Dronedarone is cost-effective, and ICERs are low versus amiodarone with €5,340; €4,620; €3,850 and €5,630 per QALY gained for Canada, Italy, Sweden and Switzerland, respectively. The most significant driving factor for the cost-effectiveness of dronedarone is the increased survival rate for patients on dronedarone.

References

Jul 6, 2000·Journal of Psychosomatic Research·N Frasure-SmithM G Bourassa
Feb 8, 2003·Stroke; a Journal of Cerebral Circulation·Josephine TengSusan Scott
Dec 14, 2006·The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care·Peter LindgrenUNKNOWN ASCOT investigators
Mar 11, 2008·Europace : European Pacing, Arrhythmias, and Cardiac Electrophysiology : Journal of the Working Groups on Cardiac Pacing, Arrhythmias, and Cardiac Cellular Electrophysiology of the European Society of Cardiology·Anna RingborgHarry J G M Crijns
Apr 9, 2008·European Journal of Cardiovascular Prevention and Rehabilitation : Official Journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology·Peter LindgrenBengt Jönsson
Feb 14, 2009·The New England Journal of Medicine·Stefan H HohnloserUNKNOWN ATHENA Investigators
Aug 14, 2009·Journal of Travel Medicine·Poh Lian LimEng Eong Ooi
Oct 3, 2009·Hepatology Research : the Official Journal of the Japan Society of Hepatology·Yasuni NakanumaAzusa Kiktao
Jan 29, 2010·Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation·Jenny BergHarry Crijns
Jul 2, 2010·The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care·Lisa EricsonIngela Björholt
Jan 14, 2011·Europace : European Pacing, Arrhythmias, and Cardiac Electrophysiology : Journal of the Working Groups on Cardiac Pacing, Arrhythmias, and Cardiac Cellular Electrophysiology of the European Society of Cardiology·Nick FreemantleMatthew Reynolds
Nov 16, 2011·The New England Journal of Medicine·Stuart J ConnollyUNKNOWN PALLAS Investigators

❮ Previous
Next ❯

Citations

Apr 30, 2013·The Canadian Journal of Cardiology·Jenny BergPeter Lindgren
Mar 7, 2018·Expert Opinion on Emerging Drugs·Alessandro CapucciIrene Giannini
Jun 26, 2013·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Sigrid PieningPeter G M Mol
Jun 3, 2014·BMC Public Health·Pauline Zardo, Alex Collie

❮ Previous
Next ❯

Related Concepts

Related Feeds

Atrial Fibrillation

Atrial fibrillation is a common arrhythmia that is associated with substantial morbidity and mortality, particularly due to stroke and thromboembolism. Here is the latest research.

Antiarrhythmic Agents: Mechanisms of Action

Understanding the mechanism of action of antiarrhythmic agents is essential in developing new medications as treatment of cardiac arrhythmias is currently limited by the reduced availability of safe and effective drugs. Discover the latest research on Antiarrhythmic Agents: Mechanism of Action here.

Anti-Arrhythmic Drug Therapies

Anti-arrhythmic drugs are used to prevent abnormal heart rhythms. These medications are used in conditions including, ventricular tachycardia, ventricular fibrillation and atrial fibrillation. Discover the latest research on anti-arrhythmic drug therapies here.

Atrial Filbrillation

Atrial fibrillation refers to the abnormal heart rhythm characterized by rapid and irregular beating of the atria. Here is the latest research.

Arrhythmia

Arrhythmias are abnormalities in heart rhythms, which can be either too fast or too slow. They can result from abnormalities of the initiation of an impulse or impulse conduction or a combination of both. Here is the latest research on arrhythmias.